158 related articles for article (PubMed ID: 21502571)
1. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial.
Wiviott SD; Flather MD; O'Donoghue ML; Goto S; Fitzgerald DJ; Cura F; Aylward P; Guetta V; Dudek D; Contant CF; Angiolillo DJ; Bhatt DL;
Circulation; 2011 May; 123(17):1854-63. PubMed ID: 21502571
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial.
O'Donoghue ML; Bhatt DL; Wiviott SD; Goodman SG; Fitzgerald DJ; Angiolillo DJ; Goto S; Montalescot G; Zeymer U; Aylward PE; Guetta V; Dudek D; Ziecina R; Contant CF; Flather MD;
Circulation; 2011 May; 123(17):1843-53. PubMed ID: 21502577
[TBL] [Abstract][Full Text] [Related]
3. Atopaxar. A novel player in antiplatelet therapy?
Wurster T; May AE
Hamostaseologie; 2012; 32(3):228-33. PubMed ID: 22859265
[TBL] [Abstract][Full Text] [Related]
4. Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease.
Rollini F; Tello-Montoliu A; Angiolillo DJ
Future Cardiol; 2012 Jul; 8(4):503-11. PubMed ID: 22871190
[TBL] [Abstract][Full Text] [Related]
5. Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program.
O'Donoghue ML; Bhatt DL; Flather MD; Goto S; Angiolillo DJ; Goodman SG; Zeymer U; Aylward PE; Montalescot G; Ziecina R; Kobayashi H; Ren F; Wiviott SD
J Thromb Thrombolysis; 2012 Jul; 34(1):36-43. PubMed ID: 22653705
[TBL] [Abstract][Full Text] [Related]
6. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.
Serebruany VL; Kogushi M; Dastros-Pitei D; Flather M; Bhatt DL
Thromb Haemost; 2009 Jul; 102(1):111-9. PubMed ID: 19572075
[TBL] [Abstract][Full Text] [Related]
7. The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs.
Kogushi M; Matsuoka T; Kawata T; Kuramochi H; Kawaguchi S; Murakami K; Hiyoshi H; Suzuki S; Kawahara T; Kajiwara A; Hishinuma I
Eur J Pharmacol; 2011 Apr; 657(1-3):131-7. PubMed ID: 21300059
[TBL] [Abstract][Full Text] [Related]
8. Platelet protease-activated receptor antagonism in cardiovascular medicine.
Wiisanen ME; Moliterno DJ
Coron Artery Dis; 2012 Sep; 23(6):375-9. PubMed ID: 22781741
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease.
Goto S; Ogawa H; Takeuchi M; Flather MD; Bhatt DL;
Eur Heart J; 2010 Nov; 31(21):2601-13. PubMed ID: 20805115
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of action and clinical development of platelet thrombin receptor antagonists.
Ueno M; Ferreiro JL; Angiolillo DJ
Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1191-200. PubMed ID: 20670195
[TBL] [Abstract][Full Text] [Related]
11. Markers of endothelial and platelet activation are associated with high on-aspirin platelet reactivity in patients with stable coronary artery disease.
Pettersen AÅ; Arnesen H; Opstad TB; Bratseth V; Seljeflot I
Thromb Res; 2012 Sep; 130(3):424-8. PubMed ID: 22795340
[TBL] [Abstract][Full Text] [Related]
12. Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin.
Undas A; Stepień E; Branicka A; Wołkow P; Zmudka K; Tracz W
Kardiol Pol; 2009 Jun; 67(6):591-8. PubMed ID: 19618315
[TBL] [Abstract][Full Text] [Related]
13. Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.
Braun OO; Johnell M; Varenhorst C; James S; Brandt JT; Jakubowski JA; Winters KJ; Wallentin L; Erlinge D; Siegbahn A
Thromb Haemost; 2008 Oct; 100(4):626-33. PubMed ID: 18841285
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials.
Capodanno D; Bhatt DL; Goto S; O'Donoghue ML; Moliterno DJ; Tamburino C; Angiolillo DJ
J Thromb Haemost; 2012 Oct; 10(10):2006-15. PubMed ID: 22845871
[TBL] [Abstract][Full Text] [Related]
15. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
Wu CC; Teng CM
Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935
[TBL] [Abstract][Full Text] [Related]
17. Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348.
Macaulay TE; Allen C; Ziada KM
Expert Opin Pharmacother; 2010 Apr; 11(6):1015-22. PubMed ID: 20307225
[TBL] [Abstract][Full Text] [Related]
18. Thrombin receptor antagonists may become an important antiplatelet therapy for coronary artery disease.
Van de Werf F
Eur Heart J; 2010 Nov; 31(21):2575-6. PubMed ID: 20805114
[No Abstract] [Full Text] [Related]
19. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease.
Serebruany V; Pokov I; Kuliczkowski W; Chesebro J; Badimon J
Thromb Haemost; 2008 Jul; 100(1):76-82. PubMed ID: 18612541
[TBL] [Abstract][Full Text] [Related]
20. Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin.
Dropinski J; Musial J; Jakiela B; Wegrzyn W; Sanak M; Szczeklik A
Thromb Haemost; 2005 Dec; 94(6):1300-5. PubMed ID: 16411409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
